Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna Inc., a clinical-stage biotechnology firm, has an enterprise value of approximately $430 million, representing a significant potential for long-term upside of 8-10 times its current share price, particularly should its collaboration with Novo prove successful. The company's diverse pipeline, including promising candidates like SEP-631, has the potential to replicate the success of existing blockbuster therapies, such as Xolair, thereby unlocking considerable market opportunities. Additionally, Septerna's proprietary Native Complex Platform and strategic partnerships, especially in the lucrative obesity market, position the company for substantial future growth and value creation.

Bears say

Septerna Inc. faces multiple risks that contribute to a negative outlook on its stock, including potential delays and setbacks in clinical development and trials for its product candidates. There are also significant concerns regarding the stability of partnerships, particularly with Novo Nordisk, and the possibility of failing to secure necessary approvals for key therapies. Furthermore, lower-than-expected market penetration rates and the risk of long-term dilution present additional financial uncertainties that could adversely affect the company's valuation.

Septerna Inc (SEPN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.